Clinical Trial Update: Dapagliflozin DPPIV Inhibitor add-on Study [Phase 3]

View source ↗

Summary

Phase 3 study assessing add-on therapy with dapagliflozin to a DPP-4 inhibitor in adults with type 2 diabetes; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• DPP-4 inhibitor (unspecified) (DPP-4 inhibitor)
• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2013-10-14